Alkermes saw a positive improvement to its Relative Strength (RS) Rating on Monday, rising from 65 to 72.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks compares to the rest of the market.
Over 100 years of market history shows that the top-performing stocks tend to have an RS Rating of above 80 in the early stages of their moves. See if Alkermes can continue to rebound and hit that benchmark.
Alkermes is working on a consolidation with a 36.45 entry. See if the stock can break out in heavy volume.
Alkermes reported negative growth for both the top and bottom lines last quarter.
The company earns the No. 22 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, Exelixis and TG Therapeutics are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
